Systematic ReviewResearchMedication SafetyPatient Education

Prenatal CFTR modulators showed promise for fetal meconium ileus, based on limited evidence

Journal of cystic fibrosis (PubMed)Aug 22, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A small individual-patient meta-analysis suggested prenatal CFTR modulator exposure may reduce surgery for fetal meconium ileus, but evidence came only from case reports and observational studies.

What NurseJet pulled from the source

Eighteen studies were included. Among 42 fetuses with cystic fibrosis and antenatally diagnosed meconium ileus who were exposed to a CFTR modulator, 12% required surgery after birth. A historical comparison suggested a possible 59.5-percentage-point reduction, but the uncontrolled evidence is highly uncertain; none of nine asymptomatic exposed fetuses developed meconium ileus.

Why this matters for nurses

Perinatal and pediatric nurses may encounter families asking about emerging prenatal treatment for cystic fibrosis complications. The review provides early evidence to discuss only within a maternal-fetal medicine and cystic fibrosis team, with clear emphasis that this is not established routine therapy.

Bedside takeaway

Frame prenatal CFTR modulator therapy as promising but experimental and keep counseling within the specialist care plan.

How This Applies in Practice

Use this when: Supporting a pregnancy affected by fetal cystic fibrosis and suspected or diagnosed meconium ileus.

On your shift

Confirm the documented fetal findings and the maternal-fetal medicine, cystic fibrosis, and neonatal consultation plan.
Use teach-back to clarify that the evidence is preliminary and that postnatal bowel assessment may still be required.
Coordinate delivery and neonatal handoff details, including the team’s plan for early assessment and surgical consultation if needed.

Keep in mind: Prenatal CFTR modulator therapy is not established by this review. Follow the specialist plan, facility policy, and provider orders.

Key takeaways

The review included 18 studies based on case reports or small observational evidence.
Among 42 exposed fetuses with diagnosed meconium ileus, the pooled proportion requiring surgery after birth was 12%.
A historical comparison suggested a possible 59.5-percentage-point reduction in surgery risk.
The lack of prospective controlled evidence prevents firm conclusions about efficacy or safety.

Practice implications

Document the fetal cystic fibrosis and bowel findings accurately, coordinate the specialist maternal and neonatal plan, and prepare families for postnatal assessment and possible surgical needs without presenting prenatal CFTR modulator use as proven standard care.

Limitations & cautions

Evidence was limited to case reports and small observational studies, used a historical rather than concurrent control, and involved few fetuses. Selection bias, reporting bias, confounding, and uncertain maternal-fetal safety limit interpretation.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Journal of cystic fibrosis (PubMed)

Journal of cystic fibrosis (PubMed). Prenatal CFTR modulator therapy and fetal meconium ileus in cystic fibrosis: a systematic review and individual patient data meta-analysis.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42632793/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Journal of midwifery & women's health (PubMed)Sep 7, 2026Research Article

A retrospective analysis of US natality data found no statistically significant yearly difference in neonatal mortality between freestanding birth centers and hospitals among term, singleton, vertex births without major medical risk factors from 2015 through 2024.

L&D / OB PedsAI summaryReview source

Research ArticleResearchPatient EducationAI summary · original source linked below

Adjusted neonatal-mortality odds for freestanding birth centers fluctuated around 1.0 across the 10-year study period. No individual year showed a statistically significant difference from hospital births, including 2020 and 2021 when birth-center volume increased.

Key takeaways

The analysis was restricted to births meeting selected low-risk criteria.
The study found no evidence that higher birth-center use during the pandemic years increased neonatal mortality.
The observational design cannot establish that birth setting itself caused the mortality pattern.

Why this matters on shift

The findings add national outcome data for counseling and systems planning around freestanding birth-center care for appropriately selected low-risk pregnancies.

Bedside takeaway

Apply local eligibility, surveillance, escalation, and transfer protocols when caring for planned low-risk birth-center patients.

Nursing implications

Keep eligibility, surveillance, escalation, and transfer decisions anchored to local birth-center criteria and maternal-newborn protocols.

Limitations & cautions

Abstract-only summary. The study used retrospective vital-record data, was limited to selected low-risk births, and cannot exclude residual differences between people who delivered in birth centers and hospitals.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of midwifery & women's health (PubMed). Neonatal Mortality Risk Among Births in Freestanding Birth Centers, 2015 to 2024.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Pediatric emergency care (PubMed)Sep 7, 2026Research Article

A double-blind randomized trial found no reduction in vomiting or faster oral tolerance with intravenous pantoprazole versus placebo in children with acute gastroenteritis and persistent vomiting after ondansetron.

Peds EmergencyAI summaryReview source

Research ArticleResearchMedication SafetyAI summary · original source linked below

The trial randomized 100 children. Vomiting episodes and oral tolerance at 6 and 12 hours did not differ significantly, while median hospital stay was 2 days with pantoprazole and 1 day with placebo.

Key takeaways

The median participant age was 14 months, and 67% of participants were male.
Oral tolerance at 12 hours was 86% in both groups.
The longer stay associated with pantoprazole requires cautious interpretation because this was a single-center trial.

Why this matters on shift

The trial does not support empiric intravenous proton-pump inhibition for persistent vomiting in pediatric acute gastroenteritis after ondansetron.

Bedside takeaway

Clarify the indication for empiric acid suppression and keep hydration and oral-tolerance assessment central to care.

Nursing implications

Prioritize the ordered hydration and oral-tolerance plan, document ongoing emesis, and clarify the indication before administering empiric acid suppression.

Limitations & cautions

Abstract-only summary. This was a single-center study of 100 children in Tehran, and the abstract does not describe adverse events or explain why hospitalization was longer in the pantoprazole group.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Pediatric emergency care (PubMed). Effect of Intravenous Pantoprazole on Clinical Outcomes in Pediatric Acute Gastroenteritis: A Placebo-Controlled RCT.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of neurology (PubMed)Sep 6, 2026Systematic Review

A cumulative meta-analysis found longer survival over time in Duchenne muscular dystrophy, alongside a shift from predominantly respiratory toward cardiac causes of death.

Peds ICUAI summaryReview source

Systematic ReviewResearchPatient EducationAI summary · original source linked below

The review included 53 studies and more than 13,000 patients. Pooled median survival was 29 years among ventilated patients and 19 years among non-ventilated patients, but these study-level observational comparisons do not establish that ventilation alone caused the difference.

Key takeaways

Sixty percent of patients in the included studies received home mechanical ventilation.
Survival improved progressively over time in both ventilated and non-ventilated groups.
As respiratory survival improved, cardiac and other causes accounted for a larger share of deaths.

Why this matters on shift

Patients living longer with Duchenne muscular dystrophy may need sustained respiratory support plus ongoing cardiac and multisystem surveillance across care transitions.

Bedside takeaway

Verify each patient's established respiratory and cardiac plan during admissions and care transitions.

Nursing implications

During admissions and handoffs, verify the established ventilation, airway-clearance, and cardiac-monitoring plan and coordinate concerns with the multidisciplinary team.

Limitations & cautions

Abstract-only summary. This was a study-level meta-analysis of heterogeneous observational survival reports; the ventilated and non-ventilated groups were not randomized, so associations should not be interpreted as treatment effects.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of neurology (PubMed). Improving survival in Duchenne muscular dystrophy across eras: a systematic review and cumulative meta-analysis.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

Low-risk birth-center births showed no higher neonatal mortality in a 10-year analysis

IV pantoprazole did not improve vomiting or oral tolerance in pediatric gastroenteritis

Duchenne survival has improved as respiratory and cardiac care evolved